Skip to main
FATE
FATE logo

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics Inc. is recognized as a leading developer of induced pluripotent stem cell (iPSC)-derived cancer therapeutics, demonstrating a strong position in the cellular therapeutics market through its innovative NK- and T-cell immuno-oncology programs. Recent presentations at key medical meetings, such as the American College of Rheumatology, have showcased positive early clinical results for their off-the-shelf CD19 CAR-T product candidate, FT819, indicating substantial improvements in patient outcomes with manageable safety profiles. The company’s approach to developing these therapies positions it favorably in the market, supported by the advantages of off-the-shelf availability, reduced manufacturing costs, and effective genetic modification capabilities.

Bears say

Fate Therapeutics Inc faces substantial risks that could adversely impact its stock performance, including the inability to showcase a significant clinical efficacy advantage of FT819 compared to existing CAR-T therapies, as well as concerns regarding safety and immunogenicity. The company's pipeline is also threatened by potential partnership-related uncertainties and unfavorable reactions from regulatory bodies, compounded by the possibility of medium-term dilution risks for shareholders. Additionally, while the clinical data demonstrates some initial efficacy in reducing B-cell counts, the transient nature of the response may raise questions about the long-term effectiveness of FT819.

Fate Therapeutics (FATE) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 6 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.